Eric Lefkofksy was recently interviewed for the Interview.net website titled, “Q&A: CEO Eric Lefkofksy and his Cancer Data Health tech Tempus Labs.” The interview took place at the 2018 Precision Medicine World Conference. Eric Lefkofksy was one of the speakers who discussed adapting big data into actionable information for the medical market.
He believes the success of Tempus is due to the problem-focused strategy. The company was designed to solve the data issue that takes place in healthcare and cancer care. He believes it is a problem that should be solved because there is a lot of data that can be mined to help physicians use the information to create a more individualized treatment plan. When he saw the difficulty of treatment first hand, he was shocked at how little data the physicians were using to solve the problem. He has spent the last twenty years creating businesses that help markets bring technology and unstructured data into the market by structuring the data at scale. He wanted to bring a similar solution to the cancer treatment market.
When he created Tempus, he used large medical systems to funnel the data and structure it. Tempus has partnered with more than 50 different cancer centers out of 69 in the U.S. Eric Lefkofsky believes they can use the data and combine it with molecular and clinical data for each patient to create a better treatment plan for each patient. The next step was creating an algorithm and analytics tool that could silo the data volume while also helping physicians understand it in real time. Working with the academic medical centers and the cancer treatment centers might have been tricky, but they believe it can have a huge impact. They created a demonstration that shows how the tool works by sifting through the clinical variability of the different drugs and therapies to create a precise treatment plan for the patient.
Tempus devised a strategy to collect data from the different patients which help oncologists learn about the best treatments for the different cancers. They can see what treatment has worked and what hasn’t. They use drug-response data and phenotypic data to see how the patients respond to different drugs.
To Visit More Click Here
Mikhail Blagosklonny is an oncologist who knows what he can do to help people. He has tried to always help his patients and he wants to make sure he is doing the best job possible to help other people who are also treating patients. He knows that the position is not one that should involve a lot of competition and that’s what has made it easier for him to show people what they can do. Mikhail Blagosklonny knows there will be different ways people can benefit from him as an oncologist, but there was no way for him to share that information in the past. He knew that the oncology industry needed a place for people to connect with each other and for people to try to make sure they were looking at different options. Know more about Mikhail at Philly Purge.
A peer review publication was the perfect place for Mikhail Blagosklonny to share this information. He started the Oncotarget peer review publication and that made it easy for him and other people to connect with each other. They could learn more about what they were doing and how they were doing things the right way. They could also show others they were going to make sure things would continue to work for them as long as they were doing the best job possible. By doing these things, Mikhail Blagosklonny felt it was his responsibility to show people how they could make things better.
Now that oncologists have a place where they can connect with each other and with other people who want to help the industry too, they feel confident in their skills and in their ability to make sure they are making all the right choices. They also know there will be things they can do to show people how it is going to get better. Mikhail Blagosklonny has always wanted to do this for others and that’s what has allowed him to keep working in the business.
Bringing attention to these issues gave Mikhail Blagosklonny the chance to make sure he was giving people what they wanted. He felt it would be important for people to try to learn more about the issues there were in the cancer treatment industry so he pushed to make things happen for everyone who was in the industry. He used Oncotarget as his way of giving people the tools that could help them with everything they had done.
As more oncologists joined the publication, Mikhail Blagosklonny felt it was his duty to make sure it was growing. He had always wanted people to realize there were things they could do and more they could learn about based on the opportunities they had. For Mikhail Blagosklonny, this was a big part of how he could work and how he could thrive as an oncologist. He wanted people to know there would be new things that would make a difference and that would give him the opportunity to try and give the community what they were looking for on their own. Read Mikhail’s plans for Oncology on Healingmagic.net.
Reaching out to Amicus Therapeutics
Whenever you are looking to get the most out of your biotechnology and medical care, it is important contact the highest quality professionals in the field. This is particularly crucial if you happen to be dealing with a disease that is rare or that you have not gotten properly diagnosed yet. By taking advantage of the services offered by Amicus Therapeutics, you will learn more information about this company and the programs that they have in place. If you are interested in more information on Amicus Therapeutics, use the tips below so that you can get help.
Who is Amicus Therapeutics?
This is a company that has provided global biotechnology for years (Google Finance). They deal with a lot of different genetic diseases, which require advancements in technology in order to continuously catch up. This company takes the needs of people who suffer from rare diseases seriously and continuously does what they can to push the industry forward. As a result, few medical professionals make as meaningful and impact in the lives of their patients as Amicus Therapeutics. This is a company that was founded in the year 2002 and is currently headquartered in Cranbury, New Jersey. They have upwards of 500 employees throughout the company and are publicly traded.
Amicus Therapeutics uses its resources in order to provide personal medical therapies to people who require this aspect of service. This is so crucial, because people who have rare diseases often struggle to get proper diagnoses and to get the best medical care available. You will be able to take full advantage of a lot of different genetic ailments – to include epidermolysis bullosa, Fabry disease and Pompe disease.
There are a lot of success stories rooted to this company due to the fact that they have saved a lot of lives by giving people accurate diagnoses and treatments. Their work is second to none in this regard and is a big reason why technology has grown by leaps and bounds throughout the medical industry. They strive to continuously give patients life-changing care every step of the process.
More here: Twitter | Facebook | Chrunchbase
Omar Boraie, featured in a NewsWise article, donated $1.5M to the Rutgers Cancer Institute in 2015. With this generous donation, Omar Boraie will have a chair named after him as a part of Rutgers Cancer Institute’s 18 chair program. The the field of science that Omar Boraie’s chair is dedicated to is genomic science.
Omar Boraie‘s donation was matched with another $1.5 million by an unknown contributor, making it a total of $3 million for genomic gcience. The development of genomic science can potentially aid doctors in cancer detection and alternative treatments. In a report by Patch.com, the Rutgers Cancer Institute is certainly ahead of the curb in cancer treatment development, being one of the few to launch genomic science related clinical trials.
Alternative treatments are becoming in demand since patients are not responding well to current treatments. The scientists with Rutgers Cancer Institute are experimenting with alternative views of cancer in order to find a cure. President Obama had even announced Precision Medicine Initiative to help with alternative cancer treatments.
With the advancement of precision medicine, scientists may be able to classify cancers into more specific types. They may even be able to determine the genetic disposition to certain types of cancers.
Omar Boraie is known for developing properties mostly in the New Brunswick area, https://local.yahoo.com/info-11014537-boraie-realty-new-brunswick. He is the owner of Boraie Development, a real estate and property development firm based in New Jersey. Many of their developments have been offices and accommodation near hospitals. View his full bio on crunchbase.com.
Boraie Development is responsible for such new structures like One Spring Street and Albany Street Plaza. They also offer property management services to help other developers and landlords rent out their properties. They also have a team dedicated towards estate sales and and marketing for other developers. They have developed many properties with the financial collaboration of the athlete Shaquille O’Neal.